e-therapeutics (ETX) News Today GBX 9 -0.65 (-6.74%) (As of 05/8/2024) Add Compare Share Share Headlines Stock AnalysisHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period AN2 Therapeutics to Meet With FDA on Epetraborole Development PathNovember 13, 2024 | marketwatch.comPositive Outlook for Akero Therapeutics Driven by Efruxifermin’s Potential and Strategic Clinical ProgramsNovember 11, 2024 | markets.businessinsider.comRBC Capital Releases a Buy Rating on Edgewise Therapeutics (EWTX)November 8, 2024 | markets.businessinsider.comAquestive Therapeutics: Progress in Drug InnovationNovember 6, 2024 | markets.businessinsider.come-therapeutics Announces Business Updates and Interim ResultsOctober 31, 2024 | markets.businessinsider.comEvecxia Therapeutics Announces Successful Completion of Pre-IND Meeting with the FDA Regarding Development of EVX-101 For DepressionOctober 27, 2024 | businesswire.comIterum Therapeutics Shares Soar on FDA's Orlynvah ApprovalOctober 25, 2024 | marketwatch.comPerspective Therapeutics (CATX) Gets a Buy from OppenheimerOctober 22, 2024 | markets.businessinsider.comETXPF e-therapeutics plcOctober 19, 2024 | seekingalpha.comTruist Financial Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)September 18, 2024 | markets.businessinsider.comERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024May 14, 2024 | markets.businessinsider.come-therapeutics plc shares now trading on JP JenkinsMay 9, 2024 | markets.businessinsider.comE-therapeutics Share ChatApril 20, 2024 | lse.co.ukEliem Therapeutics to buy Tenet, announces $120 million private placementApril 11, 2024 | msn.comAquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024April 10, 2024 | seekingalpha.come-Therapeutics says company faces lack of interest as UK listingApril 10, 2024 | lse.co.uke-Therapeutics Shares Fall on London Delisting Plan; Mulls Move to New YorkApril 10, 2024 | marketwatch.com‘Lack of appetite’ in London drives another high-tech firm to NasdaqApril 10, 2024 | msn.comDrug discovery firm e-therapeutics to quit London Stock Exchange following £29m fundraiseApril 10, 2024 | msn.come-therapeutics (LON:ETX) Stock Passes Below 200 Day Moving Average of $12.11e-therapeutics (LON:ETX) Share Price Passes Below 200-Day Moving Average of $12.11April 2, 2024 | marketbeat.comAquestive maps out FDA approval for sublingual anaphylaxis drugMarch 16, 2024 | msn.come-therapeutics (LON:ETX) Stock Price Crosses Below Two Hundred Day Moving Average of $12.41e-therapeutics (LON:ETX) Stock Crosses Below 200 Day Moving Average of $12.41March 15, 2024 | marketbeat.come-therapeutics (LON:ETX) Shares Pass Below 200-Day Moving Average of $12.52e-therapeutics (LON:ETX) Share Price Passes Below Two Hundred Day Moving Average of $12.52March 7, 2024 | marketbeat.comWe're Hopeful That e-therapeutics (LON:ETX) Will Use Its Cash WiselyJanuary 3, 2024 | finance.yahoo.comMedical innovator e-therapeutics to stop trading on US-based marketDecember 27, 2023 | msn.comEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discoveryNovember 13, 2023 | markets.businessinsider.comEvecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot EhrichOctober 30, 2023 | businesswire.comE-therapeutics bolsters generative AI integration and strategic...October 26, 2023 | proactiveinvestors.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 28, 2023 | benzinga.comQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldSeptember 28, 2023 | marketwatch.come-therapeutics appoints new CFOSeptember 20, 2023 | proactiveinvestors.comETX.L - e-Therapeutics plcJuly 13, 2023 | uk.finance.yahoo.comElicio Therapeutics Inc.June 8, 2023 | wsj.comAgeX Therapeutics Announces Appeal of NYSE American DeterminationMay 23, 2023 | businesswire.comRapid Dose Therapeutics Launches QuickStrip™ Dental Products in the Canadian MarketMay 10, 2023 | businesswire.comDelix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001May 10, 2023 | marketwatch.comAcute Renal Failure Therapeutics Market Located Worldwide Trends and Application – Baxter,Teva Pharmaceutical,PfizerMay 6, 2023 | marketwatch.comE-Therapeutics FY 2023 Pretax Loss Widened on Higher R&D CostsMay 4, 2023 | marketwatch.come-Therapeutics working to capitalise on AI "blindside"May 4, 2023 | finance.yahoo.comRelief Therapeutics Announces Results of Extraordinary General Meeting of ShareholdersApril 28, 2023 | markets.businessinsider.com8-K: Seres Therapeutics, Inc.April 28, 2023 | marketwatch.comAquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film to Additional Global MarketsMarch 30, 2023 | marketwatch.come-Therapeutics plc (ETX.L)February 26, 2023 | uk.finance.yahoo.comAkero Therapeutics Stock (NASDAQ:AKRO), Quotes and News SummaryJanuary 5, 2023 | benzinga.comAkero Therapeutics Announces Breakthrough Therapy Designation For EfruxiferminDecember 8, 2022 | markets.businessinsider.come-therapeutics raises £13.5mln via a direct subscription by funds run by M&GSeptember 30, 2022 | proactiveinvestors.come-therapeutics: Fundraise of £13.5 millionSeptember 30, 2022 | finance.yahoo.comEmergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M DealSeptember 6, 2022 | finance.yahoo.comWHO recommends monoclonal antibody treatments for Ebola diseaseAugust 21, 2022 | msn.comCompanies Like e-therapeutics (LON:ETX) Are In A Position To Invest In GrowthAugust 4, 2022 | finance.yahoo.com Get e-therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! ETX Media Mentions By Week ETX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETX News Sentiment▼0.000.47▲Average Medical News Sentiment ETX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETX Articles This Week▼00▲ETX Articles Average Week Get e-therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BVXP News ARIX News AVCT News HVO News FARN News SCLP News FUM News REDX News POLB News C4XD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:ETX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share e-therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
